Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastric Motility Clear all
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

NCT02505945
View directory record Official record
Conditions
GERD Gastroesophageal Reflux Disease
Interventions
Omeprazole, LINX Reflux Management System
Drug · Device
Lead sponsor
Torax Medical Incorporated
Industry
Eligibility
21 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Mobile, Alabama • Heber Springs, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Not applicable Interventional

Quantifying Effects of Treatment of Pediatric Dysphonia

NCT00237679
View directory record Official record
Conditions
Voice Disorders, Gastroesophageal Reflux
Interventions
Neuromuscular Electrical Stimulation, Unstimulated
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

NCT06693622
View directory record Official record
Conditions
Gastro Esophageal Reflux Disease, Barrett Esophagus
Interventions
Patient survey
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants

NCT05777512
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Gastric Feeds, Jejunal Feeds
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Hours to 1 Year
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

NCT02210000
View directory record Official record
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Withdrawn Not applicable Interventional

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

NCT03270722
View directory record Official record
Conditions
Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions
FLIP topography, Upper Endoscopy
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Results available

Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis

NCT02022826
View directory record Official record
Conditions
Gastroparesis
Interventions
SmartPill Monitoring System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Palo Alto, California • Largo, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Recruiting Not applicable Interventional

Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass

NCT04901429
View directory record Official record
Conditions
GERD
Interventions
Truncal vagotomy
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed No phase listed Observational

Gastric Bypass After Previous Anti-reflux Surgery

NCT01041105
View directory record Official record
Conditions
Clinically Severe Obesity, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated No phase listed Observational

Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification

NCT01173484
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
16 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers

NCT02736799
View directory record Official record
Conditions
Gastroparesis
Interventions
Sham vibrating capsule, Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH

NCT00818870
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Omeprazole, Vecam
Drug
Lead sponsor
Vecta Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

NCT06899217
View directory record Official record
Conditions
Idiopathic Gastroparesis
Interventions
CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
85
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule

NCT02445014
View directory record Official record
Conditions
Healthy, Barrett's Esophagus, Gastric Acid Reflux
Interventions
MGH SECM Imaging Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Available No phase listed Expanded access

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

NCT04474990
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis
Interventions
Tradipitant
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
U.S. locations
15
States / cities
Maitland, Florida • Tampa, Florida • Wauconda, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

NCT00284908
View directory record Official record
Conditions
Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions
S-Tenatoprazole-Na (STU-Na)
Drug
Lead sponsor
STEBA France
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study

NCT04500288
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
LEFT Device
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Active, not recruiting No phase listed Observational

Gastric Ultrasound for Estimation of the Aspiration Risk Study

NCT03310528
View directory record Official record
Conditions
Respiratory Aspiration of Gastric Contents
Interventions
Interview questionnaire, Gastric ultrasound exam
Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

NCT02357420
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
Relamorelin, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
70
States / cities
Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
No Longer Available No phase listed Expanded access

Treatment Use of Domperidone for Gastroparesis

NCT02227927
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, GERD, Gastroparesis
Interventions
Domperidone
Drug
Lead sponsor
Scott Gabbard, MD
Other
Eligibility
18 Years and older
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 2, 2026, 5:41 AM EDT